Study of Efficacy and Safety of Ligelizumab in Adolescents and Adults With Chronic Inducible Urticaria Who Remain Symptomatic Despite Treatment With H1- Antihistamines

Inclusion Criteria: * Confirmed CINDU diagnosis (as per guidelines) for symptomatic dermographism, cold urticaria or cholinergic urticaria for ≥ 4 months. * Diagnosis of CINDU (symptomatic dermographism, cold urticaria or cholinergic urticaria) inadequately controlled with H1-AH at local label approved doses at the time of randomization, as defined by all of the following: * Positive response (i.e development of symptoms) to triggers despite treatment with H1-AH * Positive response (i.e. development of symptoms) to provocation test on day of randomization * Participants must be able to physically perform the protocol defined provocation test specific to the participant's CINDU. * Cholinergic urticaria participants must show sweating in performing the pulse-controlled ergometry test on day of randomization. Participants with anhidrosis must not be included. * Willing and able to complete a daily symptom eDiary as per protocol requirement and adhere to the study visit schedules Exclusion Criteria: * History of hypersensitivity to any of the study drugs or its components or to drugs of similar chemical classes or to the provocation test or items used in provocation tests * Participants who have concomitant CSU at screening * Participants who have a familial form of the target CINDU that is being considered for the participant's inclusion in this study * Participants having a more defined other form of inducible urticaria than the target CINDU that is being…